KliFoCenter GmbH

Research site

Germany Diakonissenstrasse 8, Mitte, 58455 Witten, Germany

3 trials recruiting
Obesity · Overweight · Pneumonia respiratory syncytial viral
Adult patients

About Specializations

KliFoCenter GmbH in Witten, Germany specialises in clinical trials of conditions such as Obesity, Overweight, Pneumonia respiratory syncytial viral, Respiratory syncytial virus bronchiolitis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Disease Research

The KliFoCenter GmbH focuses on atherosclerotic cardiovascular disease and related conditions, aiming to test new therapies that lower the risk of heart attacks, strokes, and other serious events. Trials compare innovative agents with standard anticoagulants to improve safety and effectiveness for patients with atrial fibrillation and high lipid risk.

Stroke and systemic embolism prevention in atrial fibrillation
Major adverse cardiovascular event reduction
Lipoprotein(a) lowering strategies
Coronary heart disease outcome studies

These studies at KliFoCenter aim to bring safer, more effective treatments to people at elevated cardiovascular risk.

Metabolic and Obesity Research

In the metabolic field, the centre investigates therapies for obesity and weight‑related health issues, evaluating how novel compounds enhance weight loss when combined with diet and exercise. The goal is to demonstrate superior outcomes compared with placebo for individuals without type‑2 diabetes.

Weight reduction without diabetes
Adjunctive peptide therapy with reduced‑calorie diet
Safety and tolerability of new metabolic agents
Impact on weight‑related complications

The research supports new options for managing obesity and improving metabolic health at KliFoCenter.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Diakonissenstrasse 8, Mitte58455 WittenGermany

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 18

More sites in Witten Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

17 clinical trials

Type 2 diabetes mellitus+2

Recruiting

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity

Recruiting

Zenagamtide for Weight Loss in Adults with Obesity

Investigational

Zenagamtide for Weight Loss in Adults with Obesity

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Cardiovascular disorder

Not recruiting

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Evolocumab
Sponsor:Amgen Inc.

Contact Research Centre

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:ISIS 678354 sodium salt
Sponsor:Ionis Pharmaceuticals Inc.

Contact Research Centre

Obesity

Not recruiting

A study testing how well cagrilintide and semaglutide help people with overweight or obesity lose weight

Investigational

A study testing how well cagrilintide and semaglutide help people with overweight or obesity lose weight

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older

Registered drugNo placebo

Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites